首頁 > 市場調查報告書 > 製藥

再生醫學

誘導性多功能幹細胞細胞（iPS細胞）生產市場規模、佔有率和成長分析（按製程、工作流程、產品、應用、最終用途和地區分類）－產業預測，2026-2033年

市場調查報告書

商品編碼

1898347

誘導性多功能幹細胞細胞（iPS細胞）生產市場規模、佔有率和成長分析（按製程、工作流程、產品、應用、最終用途和地區分類）－產業預測，2026-2033年

Induced Pluripotent Stem Cells Production Market Size, Share, and Growth Analysis, By Process (Manual, Automated), By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End-Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，iPS 細胞（誘導性多功能幹細胞）生產市場規模將達到 16.8 億美元，到 2025 年將成長至 18.4 億美元，到 2033 年將成長至 38.3 億美元，在預測期（2026-2033 年）內複合年成長率為 9.6%。

在再生醫學和細胞治療領域，全球誘導多功能細胞（iPS細胞）生產市場正經歷顯著的成長和創新。 iPS細胞源自成人細胞，經重編程為多功能細胞，在個人化治療和疾病建模方面具有巨大的潛力。推動這一市場發展的因素是人們對iPS細胞應用的認知不斷加深，涵蓋從藥物研發到多種疾病治療的各個方面。研究人員和生物技術公司正在探索創新方法，以提高iPS細胞的生產效率，並確保其擴充性和成本效益。學術界、產業界和醫療機構之間的合作正在推動該領域的進步。此外，嚴格的法規結構和倫理考量對於規範iPS細胞生產至關重要，凸顯了標準化方法和安全通訊協定的必要性。這些因素共同促成了市場的持續擴張和治療方法的突破性進展。

iPS細胞生產市場促進因素

全球誘導多能幹細胞（iPS細胞）生產市場的主要驅動力是再生醫學領域的持續進步。 iPS細胞在為多種疾病開發個人化、有效的治療方法方面具有巨大潛力，這促使人們加大對研發的投入。這些創新不僅拓展了iPS細胞的應用範圍，也帶來了突破性的治療方案，吸引了製藥公司和醫療機構的資金籌措。因此，該領域的持續發展在推動市場成長和拓展新治療方法及新技術的機會方面發揮關鍵作用。

限制iPS細胞生產市場的因素

阻礙全球誘導多能幹細胞（iPSC）生產市場發展的關鍵因素之一是各種倫理和監管方面的挑戰。圍繞人源材料的倫理問題以及iPSC技術被濫用的風險，導致多個地區實施了嚴格的監管措施。這些障礙阻礙了研究活動，增加了合規成本，並加劇了市場的不確定性，最終影響了iPSC的應用和商業化進程。在相關人員應對這些複雜挑戰的過程中，整個iPSC市場的成長和發展可能會受到阻礙，導致創新和應用進程的延誤。

iPS細胞生產市場趨勢

誘導性多功能幹細胞細胞（iPS細胞）生產市場正經歷顯著的成長趨勢，這主要得益於iPS細胞技術在疾病建模領域日益廣泛的應用。研究人員和製藥公司正擴大利用iPS細胞來建構疾病特異性細胞株，從而能夠以更精準、更個人化的方式模擬多種疾病，包括遺傳性疾病、神經退化性疾病疾病和心血管疾病。這項策略轉變不僅加速了藥物發現和研發進程，也提高了標靶有效治療策略的可行性。隨著精準醫療日益受到關注，對iPS細胞技術的需求必將重塑未來生物醫學研究和治療的模式。

FUJIFILM Cellular Dynamics（USA）
Astellas Pharma（Japan）
Thermo Fisher Scientific（USA）
Takara Bio（Japan）
Lonza Group（Switzerland）
Merck KGaA（Germany）
ReproCELL（Japan）
STEMCELL Technologies（Canada）
Fate Therapeutics（USA）
Cynata Therapeutics（Australia）
Axol Bioscience（UK）
Ncardia（Belgium）
Pluricell Biotech（Brazil）
Evotec（Germany）
BioTime（USA）
Cellular Engineering Technologies（USA）
StemoniX（USA）
BrainXell（USA）
EMD Millipore（USA）
R&D Systems（USA）

結論與建議

簡介目錄

Product Code: SQMIG35H2225

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.68 Billion in 2024 and is poised to grow from USD 1.84 Billion in 2025 to USD 3.83 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global market for induced pluripotent stem cell (iPSC) production is experiencing significant growth and innovation within the field of regenerative medicine and cellular therapy. iPSCs, derived from adult cells and reprogrammed to a pluripotent state, offer immense potential for personalized treatments and disease modeling. This market is fueled by an increasing understanding of iPSCs' applications, which range from drug discovery to treating various medical conditions. Researchers and biotechnology firms are pursuing innovative approaches to enhance iPSC production efficiency, ensuring both scalability and cost-effectiveness. Partnerships between academia, industry, and healthcare organizations are driving progress in the sector. Additionally, stringent regulatory frameworks and ethical considerations are crucial in shaping iPSC production, highlighting the need for standardized practices and safety protocols, positioning the market for continued expansion and groundbreaking therapeutic advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driver of the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. IPSCs offer tremendous potential for creating personalized and effective treatments for a wide range of medical conditions, which in turn stimulates substantial investments in research and development. These innovations not only broaden the applications of iPSCs but also introduce groundbreaking therapeutic solutions, thereby attracting funding from pharmaceutical companies and healthcare institutions. As such, the continuous evolution in this field plays a crucial role in propelling market growth and expanding opportunities for new therapies and technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant factor hindering the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory challenges present. The ethical implications surrounding human-derived materials and the risk of misuse of iPSC technology have led to the implementation of stringent regulations in various regions. These obstacles can impede research initiatives, increase compliance costs, and foster market uncertainty, ultimately affecting the speed at which iPSCs are adopted and commercialized. As stakeholders navigate these complexities, the overall growth and development of the iPSC market may be adversely impacted, leading to potential delays in innovation and application.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The Induced Pluripotent Stem Cells (iPSC) production market is experiencing a significant trend driven by the growing integration of iPSC technology in disease modeling. Researchers and pharmaceutical companies are increasingly utilizing iPSCs to generate disease-specific cell lines, facilitating a more accurate and personalized approach to modeling various illnesses, including genetic disorders, neurodegenerative diseases, and cardiovascular conditions. This strategic shift not only accelerates drug discovery and development processes but also enhances the potential for targeted and effective therapeutic strategies. As precision medicine continues to gain traction, the demand for iPSC technology is set to reshape the future landscape of biomedical research and treatment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2026-2033)

Market Overview
Manual
Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2026-2033)

Market Overview
Reprogramming
Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2026-2033)

Market Overview
Consumables & Kits
Instruments
Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2026-2033)

Market Overview
Drug Development & Discovery
Regenerative Medicine
Toxicology Studies
Disease Modeling
Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2026-2033)

Market Overview
Academic & Research Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2026-2033)

North America (Process, Workflow, Product, Application, End-Use)
- US
- Canada
Europe (Process, Workflow, Product, Application, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Process, Workflow, Product, Application, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Process, Workflow, Product, Application, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Process, Workflow, Product, Application, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

FUJIFILM Cellular Dynamics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ReproCELL (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
STEMCELL Technologies (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Axol Bioscience (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ncardia (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluricell Biotech (Brazil)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTime (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellular Engineering Technologies (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemoniX (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BrainXell (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EMD Millipore (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
R&D Systems (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments